Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Ultragenyx Pharmaceutical Inc. (RARE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update Second quarter 2023 total revenue of $108.3 million, Crysvita® revenue of $83.0 million and Dojolvi® revenue of $16.5 million Total revenue grew 21% and total Crysvita revenue grew 20% versus the second quarter 2022 Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million NOVATO, Calif. – Aug 03, 2023 – Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter ended June 30, 2023 and provided its financial guidance fo..."
07/12/2023 8-K Quarterly results
07/06/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab for the Treatment of Osteogenesis Imperfecta Pivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatric and young adult patients Newly initiated Phase 3 Cosmic study now enrolling approximately 65 younger pediatric patients"
06/30/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/18/2023 144 Form 144 - Report of proposed sale of securities:
05/17/2023 8-K Other Events  Interactive Data
05/04/2023 144 Form 144 - Report of proposed sale of securities:
05/04/2023 8-K Quarterly results
04/24/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/24/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/14/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 5.8% stake in ULTRAGENYX PHARMACEUTICAL INC
02/14/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 9.1% stake in Ultragenyx Pharmaceutical Inc.
02/06/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/03/2023 SC 13G BlackRock Inc. reports a 6.2% stake in ULTRAGENYX PHARMACEUTICAL INC
01/10/2023 SC 13G/A FEDERATED HERMES, INC. reports a 4.4% stake in ULTRAGENYX PHARMACEUTICAL, INC.
01/06/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones Preliminary 2022 Total Product Revenue of $352 million to $356 million, Crysvita® Revenue in Ultragenyx Territories1 of $257 million to $258 million and Dojolvi® revenue of $55 million to $56 million 2023 expected Total Product Revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million Year-end 2022 cash balance of approximately $900 million and 2023 guidance for net cash used in operations expected to be less than $400 million"
12/09/2022 SC 13G/A Capital International Investors reports a 2.4% stake in Ultragenyx Pharmaceutical Inc.
11/10/2022 8-K Quarterly results
11/02/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/02/2022 8-K Quarterly results
10/28/2022 8-K Quarterly results
09/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/10/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
07/28/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/28/2022 8-K Quarterly results
07/18/2022 8-K Quarterly results
07/14/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy